Among these, HER2 (human epidermal growth factor receptor 2, or Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2)), a gene more commonly associated with breast cancer, has emerged as an important oncogenic driver in NSCLC, particularly within the adenocarcinoma subtype. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.